claude allary | Université Paris II - Panthéon-Assas (original) (raw)
Uploads
Papers by claude allary
The therapeutic peptides market emerged in the 1970s, when Novartis launched Lypressin, a vasopre... more The therapeutic peptides market emerged in the 1970s, when Novartis launched Lypressin, a vasopressin analogue. Since then, approximately 30 peptides have reached the market, representing a €5.3 billion opportunity in 2003 (over 1.5 per cent of the €325 billion global pharmaceutical market). Among the different classes of peptides, GNRH/LHRH agonists (leuprorelin, goserelin) account for almost 50 per cent of the market. Other key commercialised peptides include sandostatin (somatostatin analogue, Novartis), glatiramer (immunomodulator peptide, Teva), salmon calcitonin (Miacalcin, Novartis) and desmopressin (DDAVP, Ferring) (see Figure 1). Therapeutic Peptides under the Spotlight 400
1and creates considerable economic strain and burden on healthcare providers, during the intense ... more 1and creates considerable economic strain and burden on healthcare providers, during the intense four- to five-month influenza season each year. Not only do challenges remain in the reduction of morbidity and mortality caused by seasonal influenza, a real threat of pandemic influenza is today a genuine and increasing concern. The current environment surrounding influenza is therefore one of significant investment, regulatory and policy change, and global co-operation efforts in an attempt to minimize the burden of seasonal influenza and maximize preparedness for a pandemic. Alongside the fiscal, economic, and medical challenges, is that of social awareness of the disease. According to Mr Peter Cook, CEO of Biota, an Australian biotech company active in developing drugs for influenza, “attitudes have to change; in fluenza is a big killer and nobody needs to die from this virus. Short-term challenges will be in overcoming apathy towards influenza, maintaining focus and continuation in...
Thèse de doctorat de Sciences de Gestion , 2018
L’objectif de la recherche a ete de tester la pertinence de 10 attributs de comportement social d... more L’objectif de la recherche a ete de tester la pertinence de 10 attributs de comportement social des fondateurs-dirigeants de start-up de biotechnologie issus de l’observation des conduites des animaux sociaux (Wilson, Sociobiology, 1975). A travers 25 entretiens approfondis reprenant l’experience des fondateurs-dirigeants et leur evaluation des facteurs contributifs a leur succes managerial sur les criteres de Wilson, nous mettons en evidence des references constantes a la biologie evolutionniste qui permettent de mieux comprendre les elements determinants de socialisation et de gouvernance des start-ups de biotechnologie. Toutes les references des dirigeants creant des analogies entre biologie cellulaire et moleculaire et entreprise sont recensees pour proposer une interpretation de la firme comme un organisme vivant. Notre travail propose des pistes en matiere de developpement des organisations et de developpement personnel issues de trois attributs sociobiologiques particuliereme...
The therapeutic peptides market emerged in the 1970s, when Novartis launched Lypressin, a vasopre... more The therapeutic peptides market emerged in the 1970s, when Novartis launched Lypressin, a vasopressin analogue. Since then, approximately 30 peptides have reached the market, representing a €5.3 billion opportunity in 2003 (over 1.5 per cent of the €325 billion global pharmaceutical market). Among the different classes of peptides, GNRH/LHRH agonists (leuprorelin, goserelin) account for almost 50 per cent of the market. Other key commercialised peptides include sandostatin (somatostatin analogue, Novartis), glatiramer (immunomodulator peptide, Teva), salmon calcitonin (Miacalcin, Novartis) and desmopressin (DDAVP, Ferring) (see Figure 1). Therapeutic Peptides under the Spotlight 400
1and creates considerable economic strain and burden on healthcare providers, during the intense ... more 1and creates considerable economic strain and burden on healthcare providers, during the intense four- to five-month influenza season each year. Not only do challenges remain in the reduction of morbidity and mortality caused by seasonal influenza, a real threat of pandemic influenza is today a genuine and increasing concern. The current environment surrounding influenza is therefore one of significant investment, regulatory and policy change, and global co-operation efforts in an attempt to minimize the burden of seasonal influenza and maximize preparedness for a pandemic. Alongside the fiscal, economic, and medical challenges, is that of social awareness of the disease. According to Mr Peter Cook, CEO of Biota, an Australian biotech company active in developing drugs for influenza, “attitudes have to change; in fluenza is a big killer and nobody needs to die from this virus. Short-term challenges will be in overcoming apathy towards influenza, maintaining focus and continuation in...
Thèse de doctorat de Sciences de Gestion , 2018
L’objectif de la recherche a ete de tester la pertinence de 10 attributs de comportement social d... more L’objectif de la recherche a ete de tester la pertinence de 10 attributs de comportement social des fondateurs-dirigeants de start-up de biotechnologie issus de l’observation des conduites des animaux sociaux (Wilson, Sociobiology, 1975). A travers 25 entretiens approfondis reprenant l’experience des fondateurs-dirigeants et leur evaluation des facteurs contributifs a leur succes managerial sur les criteres de Wilson, nous mettons en evidence des references constantes a la biologie evolutionniste qui permettent de mieux comprendre les elements determinants de socialisation et de gouvernance des start-ups de biotechnologie. Toutes les references des dirigeants creant des analogies entre biologie cellulaire et moleculaire et entreprise sont recensees pour proposer une interpretation de la firme comme un organisme vivant. Notre travail propose des pistes en matiere de developpement des organisations et de developpement personnel issues de trois attributs sociobiologiques particuliereme...